Profile data is unavailable for this security.
About the company
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
- Revenue in USD (TTM)7.99m
- Net income in USD-40.58m
- Incorporated2014
- Employees41.00
- LocationCue Biopharma Inc40 Guest StreetBOSTON 02135United StatesUSA
- Phone+1 (617) 949-2680
- Fax+1 (302) 655-5049
- Websitehttps://www.cuebiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABVC Biopharma Inc | 508.39k | -1.81m | 60.05m | 16.00 | -- | 10.19 | -- | 118.11 | -0.1434 | -0.1434 | 0.0392 | 0.3514 | 0.0347 | -- | 0.7076 | 31,774.38 | -15.15 | -105.17 | -32.38 | -217.00 | 99.90 | 75.19 | -437.11 | -2,124.21 | 0.2166 | -2.44 | 0.1706 | -- | 234.31 | -6.20 | 37.05 | -- | -- | -- |
| Medicinova Inc | 0.00 | -11.16m | 60.33m | 13.00 | -- | 1.21 | -- | -- | -0.2275 | -0.2275 | 0.00 | 1.02 | 0.00 | -- | -- | 0.00 | -19.35 | -15.56 | -20.16 | -16.17 | -- | -- | -- | -1,144.98 | -- | -- | 0.00 | -- | -100.00 | -- | -28.91 | -- | -39.68 | -- |
| Inotiv Inc | 480.40m | -87.47m | 60.80m | 1.98k | -- | 0.3855 | -- | 0.1266 | -3.18 | -3.18 | 16.98 | 4.59 | 0.6076 | 9.00 | 7.03 | 242,995.50 | -11.06 | -20.84 | -17.98 | -25.17 | 21.87 | 27.38 | -18.21 | -30.94 | 1.18 | -1.03 | 0.7184 | -- | -14.27 | 62.27 | -3.14 | -- | 26.53 | -- |
| Ikena Oncology Inc | 0.00 | -41.71m | 60.81m | 9.00 | -- | 0.5142 | -- | -- | -0.8643 | -0.8643 | 0.00 | 2.45 | 0.00 | -- | -- | 0.00 | -27.47 | -29.58 | -29.30 | -33.67 | -- | -- | -- | -407.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.77 | -- | -- | -- |
| Avalo Therapeutics Inc | 441.00k | -21.10m | 61.28m | 23.00 | 0.2583 | 0.4998 | 0.8363 | 138.97 | 21.91 | 21.91 | 0.0496 | 11.32 | 0.0034 | -- | -- | 19,173.91 | 55.68 | -94.60 | 356.71 | -128.31 | 164.85 | 81.11 | 16,556.01 | -790.66 | -- | -- | 0.00 | -- | -77.08 | -42.05 | -11.37 | -- | -- | -- |
| Werewolf Therapeutics Inc | 1.14m | -72.41m | 62.82m | 46.00 | -- | 1.10 | -- | 54.96 | -1.64 | -1.64 | 0.0259 | 1.28 | 0.008 | -- | -- | 24,847.83 | -50.84 | -33.10 | -57.48 | -36.81 | -- | -- | -6,335.17 | -593.05 | -- | -- | 0.3169 | -- | -90.55 | -- | -88.70 | -- | -0.919 | -- |
| Artiva Biotherapeutics Inc | 0.00 | -71.72m | 63.10m | 96.00 | -- | 0.3739 | -- | -- | -3.19 | -3.19 | 0.00 | 6.93 | 0.00 | -- | -- | 0.00 | -50.97 | -44.57 | -55.41 | -51.09 | -- | -- | -- | -596.66 | -- | -- | 0.0008 | -- | -99.25 | -- | -127.62 | -- | 18.74 | -- |
| Cue Biopharma Inc | 7.99m | -40.58m | 63.29m | 41.00 | -- | 7.89 | -- | 7.92 | -0.6644 | -0.6644 | 0.1278 | 0.1064 | 0.2097 | -- | 11.42 | 194,902.40 | -106.51 | -60.20 | -190.46 | -73.56 | -- | -- | -507.87 | -683.99 | -- | -- | 0.339 | -- | 69.16 | 21.84 | 19.83 | -- | 7.32 | -- |
| Sutro Biopharma Inc | 66.43m | -245.22m | 64.69m | 269.00 | -- | -- | -- | 0.9737 | -2.98 | -2.98 | 0.808 | -0.306 | 0.1833 | -- | 2.96 | 214,303.20 | -67.66 | -31.36 | -95.74 | -37.63 | -- | -- | -369.11 | -152.29 | -- | -- | -- | -- | -59.64 | 7.74 | -112.99 | -- | -2.30 | -- |
| Atara Biotherapeutics Inc | 199.73m | -15.64m | 64.99m | 89.00 | -- | -- | -- | 0.3254 | -4.50 | -4.50 | 23.55 | -9.30 | 1.76 | 4.91 | 8.93 | 1,305,438.00 | -13.76 | -67.79 | -- | -93.07 | 80.24 | -- | -7.83 | -558.47 | 0.5676 | 0.3215 | -- | -- | 1,404.02 | -- | 69.07 | -- | -46.73 | -- |
| Repare Therapeutics Inc | 1.07m | -127.89m | 65.19m | 129.00 | -- | 0.5212 | -- | 60.76 | -3.01 | -3.01 | 0.0253 | 2.92 | 0.0053 | -- | 0.0833 | 8,317.83 | -62.83 | -24.80 | -71.53 | -28.19 | -- | -- | -11,919.29 | -150.65 | -- | -- | 0.00 | -- | 4.58 | -- | 9.71 | -- | -- | -- |
| Adicet Bio Inc | 0.00 | -117.32m | 65.34m | 152.00 | -- | 0.4047 | -- | -- | -1.29 | -1.29 | 0.00 | 1.95 | 0.00 | -- | -- | 0.00 | -48.44 | -36.24 | -52.09 | -39.41 | -- | -- | -- | -813.80 | -- | -- | 0.00 | -- | -- | -- | 17.90 | -- | 32.77 | -- |
| Forte Biosciences Inc | 0.00 | -43.71m | 65.57m | 14.00 | -- | 1.71 | -- | -- | -13.86 | -13.86 | 0.00 | 5.84 | 0.00 | -- | -- | 0.00 | -110.01 | -64.69 | -130.27 | -71.52 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.71 | -- | -38.72 | -- |
| CervoMed Inc | 9.31m | -18.67m | 65.88m | 15.00 | -- | 1.90 | -- | 7.08 | -2.14 | -2.14 | 1.07 | 3.98 | 0.3997 | -- | 11.43 | 620,547.30 | -80.17 | -54.89 | -93.42 | -60.99 | -- | -- | -200.58 | -428.45 | -- | -- | 0.00 | -- | 36.29 | -- | -650.08 | -- | -- | -- |
| Applied Therapeutics Inc | 266.00k | -43.51m | 66.53m | 35.00 | -- | 1.81 | -- | 250.10 | -0.3023 | -0.3023 | 0.0018 | 0.259 | 0.0026 | -- | -- | 7,600.00 | -41.81 | -142.89 | -81.89 | -278.61 | -- | -- | -16,357.52 | -4,856.82 | -- | -- | 0.00 | -- | -95.45 | -- | 11.81 | -- | -- | -- |
Data as of Jul 18 2025. Currency figures normalised to Cue Biopharma Inc's reporting currency: US Dollar USD
17.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bleichroeder LPas of 31 Mar 2025 | 5.00m | 7.89% |
| The Vanguard Group, Inc.as of 31 Mar 2025 | 2.30m | 3.64% |
| Park City Capital LLCas of 05 Jun 2024 | 1.00m | 1.58% |
| Geode Capital Management LLCas of 31 Mar 2025 | 693.89k | 1.10% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 559.80k | 0.88% |
| Robertson Stephens Wealth Management LLC (Invt Mgmt)as of 31 Mar 2025 | 478.50k | 0.76% |
| Sigma Planning Corp.as of 31 Mar 2025 | 326.26k | 0.52% |
| Bank of America, NA (Private Banking)as of 31 Mar 2025 | 324.34k | 0.51% |
| Advisory Research, Inc.as of 31 Mar 2025 | 257.23k | 0.41% |
| 1919 Investment Counsel LLCas of 31 Mar 2025 | 196.56k | 0.31% |
More ▼
Data from 05 Jun 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
